0M4 Stock Overview
A clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Mersana Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.88 |
| 52 Week High | US$5.34 |
| 52 Week Low | US$1.05 |
| Beta | 1.47 |
| 11 Month Change | 5.84% |
| 3 Month Change | 41.06% |
| 1 Year Change | 42.82% |
| 33 Year Change | -69.36% |
| 5 Year Change | -45.22% |
| Change since IPO | -84.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0M4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.3% | -0.2% | 0.8% |
| 1Y | 42.8% | -16.9% | 9.1% |
Return vs Industry: 0M4 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 0M4 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 0M4 volatility | |
|---|---|
| 0M4 Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0M4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0M4's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 123 | Marty Huber | www.mersana.com |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
Mersana Therapeutics, Inc. Fundamentals Summary
| 0M4 fundamental statistics | |
|---|---|
| Market cap | €240.11m |
| Earnings (TTM) | -€71.10m |
| Revenue (TTM) | €33.19m |
7.1x
P/S Ratio-3.3x
P/E RatioIs 0M4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0M4 income statement (TTM) | |
|---|---|
| Revenue | US$34.84m |
| Cost of Revenue | US$72.23m |
| Gross Profit | -US$37.39m |
| Other Expenses | US$37.23m |
| Earnings | -US$74.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | -107.33% |
| Net Profit Margin | -214.19% |
| Debt/Equity Ratio | 2,426.8% |
How did 0M4 perform over the long term?
See historical performance and comparison